Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;92(11):2821-2829.
doi: 10.1002/jmv.26183. Epub 2020 Jun 29.

Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China

Affiliations

Impact of comorbidities on patients with COVID-19: A large retrospective study in Zhejiang, China

Chanyuan Ye et al. J Med Virol. 2020 Nov.

Abstract

Coronavirus disease 2019 (COVID-19) has become a serious public health problem worldwide. Here, we stratified COVID-19 patients based on their comorbidities to assess their risk of serious adverse outcomes. We collected 856 hospitalized cases diagnosed with COVID-19 from 17 January to 7 February 2020, in Zhejiang Province, and analyzed their comorbidities and composite endpoint (including admission to intensive care unit owing to disease progression, shock, invasive ventilation, and death) to determine the relationship between comorbidities and adverse outcomes. The median age of patients was 46 (36-56) years; 439 (51.3%) were men, 242 (28.3%) had comorbidities, and 152 (17.8%) had two or more comorbidities. The most common comorbidity was hypertension (142 [16.6%]), followed by diabetes (64 [7.5%]). Of the 856 patients, there are 154 (18.0%) severe cases. Thirty-two (3.7%) reached composite endpoints, of which 22 (9.1%) were from the comorbidity group and 10 (1.6%) from the non-comorbidity group (P < .001). After adjusting for age and gender status, the risk of reaching the composite endpoint was higher in the group with comorbidity than in that without comorbidity (hazard ratio [HR] 3.04, 95% confidence interval [CI]: 1.40-6.60). HR values for patients with one, two, and three or more comorbidities were 1.61 (95% CI: 0.44-5.91), 3.44 (95% CI: 1.31-9.08), and 6.90 (95% CI: 2.69-17.69), respectively. COVID-19 patients with comorbidities had worse clinical outcomes as compared with those without any comorbidity. The higher the number of comorbidities, the greater was the risk of serious adverse outcomes.

Keywords: COVID-19; adverse outcome; comorbidity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of the time‐dependent risk of reaching to the composite endpoints. A, Comparison of time‐dependent risk of reaching the composite endpoints in patients with comorbidities (red curve) and without comorbidities (blue curve). B, Comparison of time‐dependent risk of reaching the composite endpoints among patients without comorbidity (blue curve), with 1comorbidity (red curve), two comorbidities (black curve) and with three or more comorbidities (green curve)
Figure 2
Figure 2
Variables and hazard ratios in cox proportional hazard models. The figure shows the hazard ratio and 95% confidence interval of some variables in the proportional risk model. P value less than .05 is considered to be statistically significant and regards as a risk factor for the occurrence of composite endpoints (admission to intensive care unit [ICU], shock, invasive mechanical ventilation, death). The scale bar in the middle is the hazard ratio. The cox proportional hazard regression model was used to determine the potential risk factors related to the endpoints with the risk ratio and 95% confidence interval (CI) reported. Age and sex status have been adjusted in the model

References

    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497‐506. - PMC - PubMed
    1. Feng Y, Ling Y, Bai T, et al. COVID‐19 with different severity: a multi‐center study of clinical features. Am J Respir Crit Care Med. 2020;201:1380‐1388. - PMC - PubMed
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054‐1062. - PMC - PubMed
    1. Assiri A, Al‐Tawfiq JA, Al‐Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13(9):752‐761. - PMC - PubMed
    1. Alqahtani FY, Aleanizy FS, Ali El Hadi Mohamed R, et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol Infect. 2018:1‐5. - PMC - PubMed

Publication types